Skip to search formSkip to main contentSkip to account menu

pomalidomide

Known as: 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide, 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione, 4-Aminothalidomide 
An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact… 
National Institutes of Health

Related topics

Related topics

13 relations
Angiogenesis InhibitionNCIt Antineoplastic Agent TerminologyPositive Regulation of ApoptosisThalidomide

Broader (2)

Angiogenesis InhibitorsImmunologic Factors

Narrower (4)

CC-4047ImnovidPomalystactimid

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis
INTRODUCTION: Multiple myeloma (MM) is most frequently diagnosed among people aged 65-74, and approximately one-third of patients… 
2018
2018
Pomalidomide Related Pulmonary Toxicity: A Case Report
Pomalidomide, an analogue of thalidomide, developed as a third generation oral immunomodulatory antineoplastic agent used for the… 
2017
2017
Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
We analyzed the treatment of newly diagnosed and relapsed/refractory multiple myeloma (NDMM/RRMM) patients with del(17p… 
2016
2016
Multiple Myeloma and Other Plasma Cell Dyscrasias
This management guide covers the symptoms, diagnosis, screening, staging, and treatment of multiple myeloma, smoldering myeloma… 
Review
2014
Review
2014
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Despite improvements in multiple myeloma therapy, the vast majority of patients continue to suffer relapses. Unfortunately, many… 
2013
2013
A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM).
8598 Background: POM is a newer IMiD immunomodulatory compound with high in vitro potency that has shown promise in combination… 
2013
2013
FDA Approves Pomalidomide (Pomalyst) for Multiple Myeloma
The FDA has approved pomalidomide (Pomalyst) to treat patients with relapsed or refractory multiple myeloma who have received at… 
2012
2012
Coffee drinking and mortality.
n engl j med 367;6 nejm.org august 9, 2012 575 protein target for immunomodulatory and antiproliferative activities of… 
Review
2011
Review
2011
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma… 
2010
2010
A phase II study of pomalidomide and dexamethasone in previously treated light-chain (AL) amyloidosis.
8025 Background: IMiDs propriety compounds have activity AL, an incurable plasma cell disorder related to multiple myeloma (MM… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)